Exploring the Interplay Between Chronic Kidney Disease and Cardiovascular Disease
HCPLive
OCTOBER 31, 2024
In this first of this 5-part series, Lerma and Lala-Trindade discuss the interplay between chronic kidney disease and cardiovascular disease.
Pentoxifylline ameliorates subclinical atherosclerosis progression in patients with type 2 diabetes and chronic kidney disease: a randomized pilot trial
Cardiovascular Diabetology
AUGUST 23, 2024
Diabetic kidney disease (DKD) is associated with a higher risk of cardiovascular disease (CVD). Pentoxifylline (PTF), a nonselective phosphodiesterase inhibitor with anti-inflammatory, antiproliferative, and a.
Kidney Disease 
129
129 
Chronic kidney disease linked to key cardiovascular risk precursor
Medical Xpress - Cardiology
SEPTEMBER 17, 2024
Overactivation of the sympathetic nervous system is a hallmark sign of chronic kidney disease (CKD) that increases the risk of cardiovascular disease. People with CKD often have impaired sympathetic baroreflex sensitivity—a measure of how well the baroreflex system regulates blood pressure changes.
Structural Racism Linked to Increased Prevalence of Kidney Disease, Diabetes, & Cardiovascular Disease
HCPLive
DECEMBER 21, 2023
A new study is raising awareness around the effects of structural racism on the prevalence of chronic health conditions.
Kidney Disease 122
122 
How CTVS Treats Diabetes Complications
CTVS
NOVEMBER 18, 2024
There are however some serious complications commonly associated with diabetes, like cardiovascular disease, kidney disease, and PAD (Peripheral Artery Disease). If managed well through proper diet and medication, those with diabetes can lead full and active lives.
Heart disease could hit up to 28 years sooner for people with CKM syndrome
American Heart News - Heart News
NOVEMBER 11, 2024
Research Highlights: Scientists conducted a simulation study to estimate the impact of cardiovascular-kidney-metabolic (CKM) syndrome on cardiovascular disease (CVD) risk prediction. The study found that adults with chronic kidney disease would have.
Kidney Disease 107
107 
Albuminuria: An Underappreciated Risk Factor for Cardiovascular Disease
Journal of the American Heart Association
JANUARY 12, 2024
ABSTRACT: Albuminuria, an established biomarker of the progression of chronic kidney disease, is also recognized as a biomarker for the risk of cardiovascular disease. Elevated urinary albumin excretion indicates kidney damage and systemic vascular disease, including myocardial capillary disease and arterial stiffness.
Achieving Diabetes Remission, For No Matter How Long, Can Lower Kidney, Cardiovascular Risk
HCPLive
JANUARY 19, 2024
Evidence from the Look AHEAD study suggests achieving remission in type 2 diabetes is associated with risk reductions in chronic kidney disease and cardiovascular disease.
Diabetes 111
111 
America’s CKM Syndrome Problem
CardiacWire
MAY 8, 2024
A new JAMA study revealed that a shocking 90% of US adults are at risk of developing cardiovascular-kidney-metabolic (CKM) syndrome, underscoring the need for preventative action before we face a wave of CKM-related heart disease. Stage 4 (heart disease, with or without kidney disease) – 9.2%
Kidney Disease 116
116 
Resting Heart Rate Independent of Cardiovascular Disease Risk Factors Is Associated With End?Stage Renal Disease: A Cohort Study Based on 476?347 Adults
Journal of the American Heart Association
DECEMBER 1, 2023
BackgroundThe relationship between resting heart rate (RHR) and the risk of end‐stage renal disease (ESRD) among those without cardiovascular disease remains unclear. These results suggest that RHR may serve as a risk factor for kidney disease in individuals without established cardiovascular disease risk factors.
Risk Factors 75
75 
Systemic inflammation prevalence in patients with atherosclerotic cardiovascular disease and chronic kidney disease: a population-based study using a nationwide primary care database in Spain
Frontiers in Cardiovascular Medicine
MARCH 3, 2025
IntroductionSystemic inflammation is recognised as a critical driver of atherosclerotic cardiovascular disease (ASCVD), especially in patients with comorbid chronic kidney disease (CKD).
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
The New England Journal of Medicine
MARCH 28, 2025
Among participants with type 2 diabetes and cardiovascular disease, chronic kidney disease, or both, oral semaglutide (14 mg) was associated with a lower risk of cardiovascular events than placebo after 4 years of follow-up.
Diabetes 75
75 
Kidney Disease as a Cardiovascular Disease Priority
Circulation
SEPTEMBER 22, 2024
Circulation, Volume 150, Issue 13 , Page 975-977, September 24, 2024.
Association between atherogenic index of plasma and future risk of cardiovascular disease in individuals with cardiovascular-kidney-metabolic syndrome stages 0–3: a nationwide prospective cohort study
Cardiovascular Diabetology
JANUARY 17, 2025
As an emerging concept, Cardiovascular-kidney-metabolic syndrome (CKM) elucidates the intricate interconnection between metabolic disorders(Mets), cardiovascular disease(CVD), and chronic kidney disease(CKD).
Endothelin System in Hypertension and Chronic Kidney Disease
Hypertension Journal
DECEMBER 7, 2023
ETs were shown to play important roles among others, in systemic hypertension, particularly when resistant or difficult to control, and in pulmonary hypertension, atherosclerosis, cardiac hypertrophy, subarachnoid hemorrhage, chronic kidney disease, diabetic cardiovascular disease, scleroderma, some cancers, etc.
Enhancing Cardiovascular Health in End-Stage Kidney Disease, with Maya N. Clark-Cutaia, PhD, RN
HCPLive
MAY 16, 2024
Clark-Cutaia, PhD, ACNP-BC, RN, highlights strategies to improve cardiovascular disease-related outcomes in patients with ESKD.
RN 59
59 
Associations Between Life's Essential 8 and Chronic Kidney Disease
Journal of the American Heart Association
DECEMBER 8, 2023
BackgroundChronic kidney disease (CKD) is closely associated with cardiovascular disease. Journal of the American Heart Association, Ahead of Print.
Semaglutide Cardiovascular Outcomes Trial
American College of Cardiology
MARCH 29, 2025
The goal of the phase 3b SOUL trial was to assess the cardiovascular efficacy of oral semaglutide, a GLP-1 receptor agonist, and to determine the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or both.
The Kidney-Immune-Brain Axis: The Role of Inflammation in the Pathogenesis and Treatment of Stroke in Chronic Kidney Disease
Stroke Journal
JANUARY 24, 2025
Cardiovascular diseases such as stroke are a major cause of morbidity and mortality for patients with chronic kidney disease (CKD). Stroke, Ahead of Print.
Oral nitrate-reducing bacteria as potential probiotics for blood pressure homeostasis
Frontiers in Cardiovascular Medicine
APRIL 4, 2024
Hypertension is a leading cause of morbidity and mortality worldwide and poses a major risk factor for cardiovascular diseases and chronic kidney disease.
Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review
Circulation
MARCH 9, 2025
Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascular risk factors.
Abstract 4142036: Association of smoking status with incident heart failure among patients with chronic kidney disease: Insights from CRIC
Circulation
NOVEMBER 11, 2024
Introduction:Smoking is a well-known risk factor for atherosclerotic cardiovascular disease and kidney failure among patients with chronic kidney disease (CKD). Circulation, Volume 150, Issue Suppl_1 , Page A4142036-A4142036, November 12, 2024. However, the association of former and current smoking status (vs.
Abstract 4148106: Hemophilia and Cardiovascular disease in the United States: Prevalence, Risk factors, and outcomes.
Circulation
NOVEMBER 11, 2024
Owing to improved management, the life expectancy of patients with hemophilia has increased significantly and predisposes them to risk of cardiovascular diseases and thrombotic events. The hemophilia cohort was slightly older (63.2[16.8]
Risk Factors 40
40 Development and Validation of AHA’s PREVENT Equations
American College of Cardiology
FEBRUARY 12, 2024
What is the value of the new American Heart Association’s (AHA’s) PREVENT equation(s) for primary prevention that use routinely available clinical variables including obesity, diabetes, kidney disease, and social risk for predicting 10- and 30-year absolute risk of cardiovascular disease (CVD) including each atherosclerotic CVD (ASCVD) and heart (..)
Overall Sleep Quality Is Associated With Advanced Stages in Patients With Cardiovascular–Kidney–Metabolic Syndrome
Journal of the American Heart Association
MARCH 25, 2025
BackgroundIn 2023, the American Heart Association defined the concept of cardiovascularkidneymetabolic (CKM) syndrome as a health disorder ascribed to connections among obesity, diabetes, chronic kidney disease, and cardiovascular disease. CKM syndrome stages 3 and 4 are considered advanced.
Understanding the failings of yesterday to improve the outcomes of tomorrow: a CardioRenal story
The British Journal of Cardiology
JULY 17, 2024
2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. Clinicians and health care systems must be encouraged to make use of these treatments.”
Your Top Five Questions About CMHC On-Demand, Answered
Cardiometabolic Health Congress
NOVEMBER 25, 2024
Don’t worry—you can still access the 19th Annual CMHC sessions through our On-Demand platform, which offers 14 CME credits across four comprehensive tracks: Cardiorenal Health: Stay up-to-date with the latest on therapies for resistant hypertension, chronic kidney disease markers, and cardiac risk assessment tools.
CME 52
52 Multimorbidity Patterns and In‐Hospital Outcomes in Chinese Young Women (Aged <55 Years) Presenting with ST‐Segment–Elevation Myocardial Infarction
Journal of the American Heart Association
MARCH 27, 2025
Six multimorbidity patterns were identified, including 4 specific patterns: (1) pattern 1, cerebrovascular cluster (histories of cerebrovascular disease and hypertension); (2) pattern 2, traditional cardiovascular disease risk factors cluster (histories of hyperlipidemia, obesity, anddiabetes, and family history of cardiovascular disease and smoking); (..)
The Cardiometabolic Event of the Year: What to Expect at the 19th Annual Cardiometabolic Health Congress (CMHC)
Cardiometabolic Health Congress
JULY 25, 2024
Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovascular disease, and chronic kidney disease.
Education 100
100 
A mechanism for the treatment of cardiovascular and renal disease
Journal of Cardiovascular Pharmacology
MARCH 13, 2024
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally. CVD and kidney disease are closely related, with kidney injury increasing CVD mortality. CVD and kidney disease are closely related, with kidney injury increasing CVD mortality.
Exploration of the Interrelationship Between Serum Uric Acid, Gout, and Cardiac, Renal, and Metabolic Conditions in Middle Aged and Older People
Journal of the American Heart Association
MARCH 27, 2025
Mendelian randomization analysis indicated that SUA was causally associated with cardiovascular disease, chronic kidney disease, and diabetes.ConclusionsHyperuricemia and gout are strong predictors of increased prevalence and mortality of CRM conditions, emphasizing the importance of managing hyperuricemia and gout in these patients.
Cardiometabolic Health Congress (CMHC) will present the results of a webcast series designed to help practitioners improve patient care
Cardiometabolic Health Congress
JUNE 24, 2024
Cardiovascular disease, diabetes, obesity, lifestyle, chronic kidney disease (CKD), metabolic dysfunction–associated steatotic liver disease (MASLD), and metabolic dysfunction–associated steatohepatitis (MASH) are other important disease considerations covered by CMHC’s catalog of in-person, live, virtual, and enduring educational offerings.
Patient Care 52
52 
Cardiometabolic Health Congress (CMHC) Launches Focused Digital Education Hubs
Cardiometabolic Health Congress
JULY 12, 2023
Through CMHC’s Cardiometabolic Education Hubs , learners can easily access an array of education related to 12 therapeutic or practice topics: Cardiovascular Disease Care Delivery Implementation Chronic Kidney Disease Clinical Array Diabetes Management Diversity, Equity, and Inclusion Hypertension Interventional Cardiology Lifestyle Management (..)
Education 40
40 
Abstract 4147019: Role of Fractional Excretion of Uric Acid as a Predictor of Cardio-renal Syndrome in Acute Decompensated Heart Failure Patients: An Observational Study
Circulation
NOVEMBER 11, 2024
However, multi-parametric techniques and biomarkers which are available for investigating cardiovascular diseases and kidney diseases may offer opportunities for the evaluation of CRS. Conclusion:The FeUa seems to be a negative predictor of CRS in patients hospitalized with ADHF.
Multi-Ethnic Study of Atherosclerosis Early Heart Failure Study: Rationale, Design, and Baseline Characteristics
Circulation: Heart Failure
MARCH 8, 2024
The prevalence of HF risk factors was high: hypertension, 61.9%; former or current smoking, 53.7%; obesity 34.8%; diabetes; 24.7%; and chronic kidney disease; 22%. Overt cardiovascular disease, which ranged from 2.1% (HF) to 13.6% (atrial fibrillation), was less common. were female, 25.6% were Black, 12.8% were White.
Abstract WP294: Racial Disparities among the risk of Stroke and other clinical outcomes post Infective Endocarditis: A Propensity Matched Analysis
Stroke Journal
JANUARY 30, 2025
Background:Racial disparities have been well described in cardiovascular disease. Primary outcome was ischemic stroke, while secondary outcomes were all-cause mortality, heart failure, cardiogenic shock, MACE (composite of all-cause mortality, heart failure, and ischemic stroke), and acute kidney injury (AKI).Result:After
Abstract 4143897: Monocyte regulation of magnesium during salt sensitivity of blood pressure
Circulation
NOVEMBER 11, 2024
Background:Dietary magnesium (Mg+2) deficiency has been linked to hypertension, chronic kidney disease, and cardiovascular disease. Circulation, Volume 150, Issue Suppl_1 , Page A4143897-A4143897, November 12, 2024. High sodium intake and reduced dietary Mg+2consumption are associated with elevated blood pressure.
Abstract 4137914: Eligibility for Semaglutide in US Adults with Diabetes and Potentially Preventable Cardiovascular Events Projected from the SUSTAIN-6 Trial
Circulation
NOVEMBER 11, 2024
Background:The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial showed cardiovascular disease (CVD) benefits of semaglutide therapy in patients with type 2 diabetes mellitus (T2DM).Purpose:To year follow-up time).Results:Among
Diabetes 40
40 
19th Annual Cardiometabolic Health Congress: Honoring the Life and Legacy of CMHC Co-Chair Dr. George L. Bakris
Cardiometabolic Health Congress
AUGUST 14, 2024
Themed “Decoding the Constellation of Cardiometabolic Health and Risk Factors,” this year’s congress will tackle the growing health threat posed by cardiometabolic diseases, affecting 47 million people in the US.
CME 72
72 
Blood pressure self-monitoring practice and associated factors among adult hypertensive patients on follow-up at South Wollo Zone Public Hospitals, Northeast Ethiopia
Open Heart
MARCH 23, 2023
It is risk factor for cardiovascular disease, stroke and kidney disease. Background Hypertension is a silent killer that causes serious health issues in all parts of the world. Self-monitoring practice has been identified as an important component of hypertension management.
Abstract 4147960: Intensive treatment compared to Standard for hypertension in elderly patients, is it safe and effective? A Systematic Review and Meta-Analysis
Circulation
NOVEMBER 11, 2024
of patients had cardiovascular disease, 10.9% chronic kidney disease. The results were reported as the pooled results using risk ratio (RR) and a confidence interval (CI) of 95%.Results:The diabetes, and 15.5%
What’s wrong with the NHS? – Part 4
Dr. Malcolm Kendrick
DECEMBER 8, 2023
In addition, there are links to formal risk assessment in cardiovascular disease. With bonus hyperlinks to NICE’s guidelines on hypertension in chronic kidney disease and type I diabetes and type II diabetes and on and on. But this, the primary guideline on hypertension for adults, is but one of many.
Abstract 151: Age?Related Increases in Carotid Artery Calcification: Insights from NaF PET/CT Imaging
Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Risk factors such as smoking, chronic kidney disease, and aging can contribute to plaque formation. The gradual loss of elasticity in arterial walls and the presence of other risk factors, such as high blood pressure and diabetes, contribute to the increased risk of cardiovascular disease (CVD) observed in aging populations.
Risk Factors 40
40 
Ozempic Approved for Diabetic Kidney Disease
Med Page Today
JANUARY 28, 2025
(MedPage Today) -- The FDA approved semaglutide (Ozempic) to reduce the risk of kidney disease worsening, kidney failure, and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD), making it the only.
Kidney Disease 104
104 
Let's personalize your content